Related Content
- Gallup: Take Care Clinics top in customer service
- The Little Clinic adds new insurance provider to accepted plans
- Bartell to cease filling Medicaid prescriptions at 15 locations
- More progress needed in health information technology
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
INDIANAPOLIS Lackluster results have prompted Eli Lilly to stop two late-stage clinical trials of a drug for treating Alzheimer’s disease, Lilly said Tuesday.
The drug maker said it would stop the phase-3 trials of semagacestat after preliminary results showed it did not slow the progression of the disease, while patients showed a worsening of cognitive functioning and the ability to perform daily activities.
Lilly said it still was investigating the monoclonal antibody solanezumab as a treatment for Alzheimer’s disease in another phase-3 trial.
